Canada
· Delayed Price · Currency is CAD PharmaCorp Rx Statistics
Total Valuation
PharmaCorp Rx has a market cap or net worth of CAD 58.63 million. The enterprise value is 33.19 million.
| Market Cap | 58.63M |
| Enterprise Value | 33.19M |
Important Dates
The next estimated earnings date is Tuesday, January 28, 2025.
| Earnings Date | Jan 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PharmaCorp Rx has 117.26 million shares outstanding. The number of shares has increased by 476.74% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 117.26M |
| Shares Change (YoY) | +476.74% |
| Shares Change (QoQ) | +103.37% |
| Owned by Insiders (%) | 13.35% |
| Owned by Institutions (%) | n/a |
| Float | 101.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 41.90 |
| PB Ratio | 1.96 |
| P/TBV Ratio | 2.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.69 |
| EV / Sales | 23.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -25.80 |
Financial Position
The company has a current ratio of 42.62, with a Debt / Equity ratio of 0.03.
| Current Ratio | 42.62 |
| Quick Ratio | 42.00 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.77 |
| Interest Coverage | -121.35 |
Financial Efficiency
Return on equity (ROE) is -12.23% and return on invested capital (ROIC) is -8.16%.
| Return on Equity (ROE) | -12.23% |
| Return on Assets (ROA) | -7.91% |
| Return on Capital (ROIC) | -8.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +152.38% in the last 52 weeks. The beta is -6.35, so PharmaCorp Rx's price volatility has been lower than the market average.
| Beta (5Y) | -6.35 |
| 52-Week Price Change | +152.38% |
| 50-Day Moving Average | 0.64 |
| 200-Day Moving Average | 0.43 |
| Relative Strength Index (RSI) | 34.52 |
| Average Volume (20 Days) | 51,567 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaCorp Rx had revenue of CAD 1.40 million and -1.99 million in losses. Loss per share was -0.02.
| Revenue | 1.40M |
| Gross Profit | 514,088 |
| Operating Income | -2.19M |
| Pretax Income | -1.99M |
| Net Income | -1.99M |
| EBITDA | n/a |
| EBIT | -2.19M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 26.68 million in cash and 989,735 in debt, giving a net cash position of 25.69 million or 0.22 per share.
| Cash & Cash Equivalents | 26.68M |
| Total Debt | 989,735 |
| Net Cash | 25.69M |
| Net Cash Per Share | 0.22 |
| Equity (Book Value) | 30.07M |
| Book Value Per Share | 0.25 |
| Working Capital | 26.65M |
Cash Flow
In the last 12 months, operating cash flow was -1.28 million and capital expenditures -6,890, giving a free cash flow of -1.29 million.
| Operating Cash Flow | -1.28M |
| Capital Expenditures | -6,890 |
| Free Cash Flow | -1.29M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 36.83%, with operating and profit margins of -156.81% and -142.45%.
| Gross Margin | 36.83% |
| Operating Margin | -156.81% |
| Pretax Margin | -142.55% |
| Profit Margin | -142.45% |
| EBITDA Margin | n/a |
| EBIT Margin | -156.81% |
| FCF Margin | n/a |
Dividends & Yields
PharmaCorp Rx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -476.74% |
| Shareholder Yield | -476.74% |
| Earnings Yield | -3.40% |
| FCF Yield | -2.19% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaCorp Rx has an Altman Z-Score of 15.53.
| Altman Z-Score | 15.53 |
| Piotroski F-Score | n/a |